Bromeo Albert John, Grulla-Quilendrino Patricia, Antolin Ruth Camille, Salcedo Emil Joshua John, Arcinue Cheryl A, De Jesus Ralph Anthony, Veloso Amadeo
Asian Eye Institute, Makati, Philippines.
Department of Ophthalmology and Visual Sciences, Philippine General Hospital, University of the Philippines, Manila, Philippines.
Int J Retina Vitreous. 2022 Aug 26;8(1):57. doi: 10.1186/s40942-022-00406-z.
To analyze the changes in foveal avascular zone (FAZ) area, perimeter, and circularity in the superficial (SCP) and deep (DCP) capillary plexuses in eyes with diabetic macular edema (DME) treated with intravitreal anti-VEGF using optical coherence tomography angiography (OCTA).
This prospective observational study included 56 eyes from 32 patients with DME that received intravitreal anti-VEGF. OCTA images were obtained at baseline and 1, 3, and 6 months of follow-up. The outcome measures were FAZ area, perimeter, and circularity in both the SCP and DCP, as well as central subfield thickness (CST) and best-corrected visual acuity (BCVA).
The mean number of intravitreal anti-VEGF injections received during the observation period was 4.60 ± 0.82 (range: 3-6). The FAZ area, perimeter, and circularity were statistically unchanged at all observation points in both the SCP (p = 0.772, p = 0.405, p = 0.157, respectively) and the DCP (p = 0.620, p = 0.769, p = 0.481, respectively). Despite having no change in the FAZ parameters, there was still a statistically significant decrease in CST (p < 0.001) as well as a statistically significant increase in BCVA (p = 0.004) during the observation period.
The FAZ area, perimeter, and circularity in the SCP and DCP as measured by OCTA remained stable during the first 6 months of intravitreal anti-VEGF therapy in eyes with DME. While there were no significant changes in the FAZ, treatment with intravitreal anti-VEGF still resulted in decreased CST and improved BCVA.
使用光学相干断层扫描血管造影(OCTA)分析接受玻璃体内抗VEGF治疗的糖尿病性黄斑水肿(DME)患者眼睛的浅表毛细血管丛(SCP)和深层毛细血管丛(DCP)中黄斑无血管区(FAZ)面积、周长和圆形度的变化。
这项前瞻性观察研究纳入了32例接受玻璃体内抗VEGF治疗的DME患者的56只眼睛。在基线以及随访的1、3和6个月时获取OCTA图像。观察指标为SCP和DCP中的FAZ面积、周长和圆形度,以及中心子场厚度(CST)和最佳矫正视力(BCVA)。
观察期间接受玻璃体内抗VEGF注射的平均次数为4.60±0.82(范围:3 - 6次)。SCP(分别为p = 0.772、p = 0.405、p = 0.157)和DCP(分别为p = 0.620、p = 0.769、p = 0.481)在所有观察点的FAZ面积、周长和圆形度在统计学上均无变化。尽管FAZ参数没有变化,但在观察期间CST仍有统计学上的显著降低(p < 0.001),BCVA也有统计学上的显著提高(p = 0.004)。
在接受玻璃体内抗VEGF治疗的DME患者眼睛中,OCTA测量的SCP和DCP中的FAZ面积、周长和圆形度在治疗的前6个月保持稳定。虽然FAZ没有显著变化,但玻璃体内抗VEGF治疗仍导致CST降低和BCVA改善。